Figure 5.
Impact of the combination treatment on the immune cells in tumor and spleen tissue. (A) Male BALB/c mice were injected i.p. with 1 × 105 CT26 cells on day 0 (D0) and treated according to TS3 (n = 4 per group). Animals were sacrificed on day 11 and tumor as well as spleen tissue collected. Statistical significance of the impact of combination treatment was calculated by unpaired t test (***p < 0.001). (B) Impact of treatment on tumor-associated activated cytotoxic T-cells (CD25+) was analysed by flow cytometry. In addition, representative dot plots from each group are shown. (C) Therapy-induced changes on NK-T cells (CD335+/CD3+), granulocytes (CD11b+/Ly6G+) and active macrophages (F4/80+/MHCII+) in tumor vs. spleen tissue were evaluated by multicolor flow cytometry. Each point represents one individual mouse. Statistical analysis was done using unpaired t test (*p < 0.05;**p < 0.01; ***p < 0.001).